

## Special Issue

# 10th Anniversary of Biomedicines—Advances in Chronic Obstructive Pulmonary Disease (COPD)

### Message from the Guest Editor

This Special Issue focuses on recent advances in diagnostics and therapeutics for COPD, which represents an increasing medical and economic burden worldwide. Understanding is now growing about public health reasons for this, such as air pollution and occupation, as well as the commonly known risk factor of cigarette smoking. Furthermore, knowledge of treatment has advanced from the generic to the specific, with newer treatments targeting pathophysiological endotypes of COPD rather than the generic management of airflow obstruction. We also understand the range of co-morbidities that COPD patients exhibit, and we are beginning to delineate shared pathophysiology and routes to therapy. Nevertheless, there remain many unanswered questions in COPD, from how to address etiological risk factors or generic treatments, particularly in resource-poor environments, to patient selection for high-cost targeted therapies, such as monoclonal antibodies. We invite the submission of research articles that will improve our knowledge on these topics, either through original research or reviews.

### Guest Editor

Prof. Dr. Alice M Turner

Centre for Translational Inflammation Research, University of Birmingham, Birmingham, UK

### Deadline for manuscript submissions

closed (30 April 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/106893](https://mdpi.com/si/106893)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).